NASDAQ:SION

Sionna Therapeutics (SION) Stock Price, News & Analysis

Sionna Therapeutics logo
$3.07 -0.05 (-1.60%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$3.12 +0.05 (+1.56%)
As of 11/17/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Sionna Therapeutics Stock (NASDAQ:SION)

Advanced

Key Stats

Today's Range
$2.99
▼
$3.17
50-Day Range
$3.07
▼
$8.26
52-Week Range
$2.99
▼
$54.97
Volume
550,734 shs
Average Volume
855,090 shs
Market Capitalization
$138.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.33
Consensus Rating
Hold

Company Overview

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, a genetic disease caused by defects in the CFTR protein. The company’s research aims to address the underlying protein dysfunction rather than only manage the symptoms of the disease.

Its pipeline includes small-molecule candidates designed to stabilize or correct CFTR, with the goal of restoring the protein’s function. Sionna is investigating these candidates as potential components of combination therapies for people with cystic fibrosis.

Founded in 2019 and based in Cambridge, Massachusetts, Sionna develops therapies for a disease affecting patients worldwide. Its programs remain in development, and the company’s focus is on advancing new treatment options for the cystic fibrosis community.

AI Generated. May Contain Errors.

Sionna Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

SION MarketRank™: 
1.854366347175 of 5 stars

Sionna Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 690th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sionna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 11 hold ratings, and 1 sell rating.

  • Upside Potential

    Sionna Therapeutics has a consensus price target of $42.33, representing about 1,278.9% upside from its current price of $3.07.

  • Amount of Analyst Coverage

    Sionna Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Sionna Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sionna Therapeutics are expected to grow in the coming year, from ($2.54) to ($2.10) per share.

  • Price to Book Value per Share Ratio

    Sionna Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.82% of the float of Sionna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sionna Therapeutics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Sionna Therapeutics has recently increased by 14.57%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Sionna Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sionna Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Sionna Therapeutics has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Sionna Therapeutics this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Sionna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,830,974.00 in company stock.

  • Percentage Held by Insiders

    5.10% of the stock of Sionna Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Sionna Therapeutics has minimal institutional ownership at this time.

  • Read more about Sionna Therapeutics' insider trading history.
Receive SION Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sionna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SION Stock News Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Headlines

SION Stock Analysis - Frequently Asked Questions

Sionna Therapeutics' stock was trading at $41.14 on January 1st, 2026. Since then, SION stock has decreased by 92.5% and is now trading at $3.07.

Sionna Therapeutics, Inc. (NASDAQ:SION) posted its earnings results on Tuesday, November, 10th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.10.

Sionna Therapeutics (SION) raised $180 million in an initial public offering (IPO) on Friday, February 7th 2025. The company issued 10,588,233 shares at a price of $16.00-$18.00 per share.

Sionna Therapeutics' top institutional shareholders include RA Capital Management L.P. (14.27%), Goldman Sachs Group Inc. (6.01%), Marshall Wace LLP (0.98%) and State Street Corp (0.83%). Insiders that own company stock include Tpg Gp A, Llc, Ra Capital Management, LP, Peter A Thompson, Orbimed Advisors Llc, Bruce Booth, Michael Cloonan and Elena Ridloff.
View institutional ownership trends
.

Shares of SION stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/10/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SION
Previous Symbol
NASDAQ:SION
CIK
2036042
Fax
N/A
Employees
59
Year Founded
N/A

Price Target and Rating

High Price Target
$63.00
Low Price Target
$5.00
Potential Upside/Downside
+1,278.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.44)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.27 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.78%
Return on Assets
-37.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.92
Quick Ratio
13.92

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.32 per share
Price / Book
0.58

Miscellaneous

Outstanding Shares
45,240,000
Free Float
42,929,000
Market Cap
$138.89 million
Optionable
Optionable
Beta
1.23
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:SION) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners